Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands

被引:44
作者
van de Laar, TJW
Langendam, MW
Bruisten, SM
Welp, EAE
Verhaest, I
van Ameijden, EJC
Coutinho, RA
Prins, M
机构
[1] Municipal Serv Amsterdam, Cluster Infect Dis, Dept Infect Dis, NL-1000 CE Amsterdam, Netherlands
[2] Municipal Hlth Serv, Dept Epidmeiol & Informat, Utrecht, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Amsterdam, Netherlands
关键词
molecular epidemiology; injecting drug use; spread of HCV; phylogeny; HCV genotypes; HCV transmission;
D O I
10.1002/jmv.20486
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To elucidate the character and magnitude of the hepatitis C virus (HCV) epidemic among drug users in Amsterdam, 197 young drug users from the period 2000 to 2004 were compared with 215 counterparts from 1985 to 1989. Although injection risk behavior and HCV seroprevalence decreased sharply over time, HCV seroprevalence remains high (44%) among young drug users who have ever injected. Phylogenetic analysis shows that current HCV infections originate from diversification of strains already circulating in the past, but also from the recent introduction of new subtypes. HCV subtypes la and 3a remain the most prevalent among drug users in Amsterdam, but other subtypes such as 4d and 2b have entered the population. In conclusion, both the unpopularity of injecting drug use and the success of prevention campaigns are likely to be responsible for the decline in the seroprevalence of HCV and increased median time to seroconversion. Treatment of those infected chronically, in combination with the continuation of prevention programs, might decrease future HCV transmission.
引用
收藏
页码:509 / 518
页数:10
相关论文
共 41 条
[1]   Change in hepatitis C virus genotype in in ecting drug users [J].
Aitken, C ;
McCaw, R ;
Jardine, D ;
Bowden, S ;
Higgs, P ;
Nguyen, O ;
Crofts, N ;
Hellard, M .
JOURNAL OF MEDICAL VIROLOGY, 2004, 74 (04) :543-545
[2]   Molecular epidemiology of hepatitis C virus in a social network of injection drug users [J].
Aitken, CK ;
McCaw, RF ;
Bowden, DS ;
Tracy, SL ;
Kelsall, JG ;
Higgs, PG ;
Kerger, MJ ;
Nguyen, H ;
Crofts, JN .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (09) :1586-1595
[3]   Epidemiological changes in hepatitis C virus genotypes in France:: evidence in intravenous drug users [J].
Bourlière, M ;
Barberin, JM ;
Rotily, M ;
Guagliardo, V ;
Portal, I ;
Lecomte, L ;
Benali, S ;
Boustière, C ;
Perrier, H ;
Jullien, M ;
Lambot, G ;
Loyer, R ;
LeBars, O ;
Daniel, R ;
Khiri, H ;
Halfon, P .
JOURNAL OF VIRAL HEPATITIS, 2002, 9 (01) :62-70
[4]   A genetic analysis of hepatitis Cvirus transmission between injection drug users [J].
Cochrane, A ;
Searle, B ;
Hardie, A ;
Robertson, R ;
Delahooke, T ;
Cameron, S ;
Tedder, RS ;
Dusheiko, GM ;
de Lamballerie, X ;
Simmonds, P .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (09) :1212-1221
[5]   Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses [J].
Garfein, RS ;
Vlahov, D ;
Galai, N ;
Doherty, MC ;
Nelson, KE .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1996, 86 (05) :655-661
[6]  
Goldberg D, 2001, SCAND J INFECT DIS, V33, P457, DOI 10.1080/00365540152029936
[7]   Hepatitis C virus infection among injection drug users - Survival analysis of time to seroconversion [J].
Hagan, H ;
Thiede, H ;
Des Jarlais, DC .
EPIDEMIOLOGY, 2004, 15 (05) :543-549
[8]  
Hagan H, 2001, AM J PUBLIC HEALTH, V91, P42, DOI 10.2105/AJPH.91.1.42
[9]   Hepatitis C virus seroconversion among young injection drug users: Relationships and risks [J].
Hahn, JA ;
Page-Shafer, K ;
Lum, PJ ;
Bourgois, P ;
Stein, E ;
Evans, JL ;
Busch, MP ;
Tobler, LH ;
Phelps, B ;
Moss, AR .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (11) :1558-1564
[10]   Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco [J].
Hahn, JA ;
Page-Shafer, K ;
Lum, P ;
Ochoa, K ;
Moss, AR .
HEPATOLOGY, 2001, 34 (01) :180-187